Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Epirubicin Plus BCG for Bladder Cancer Recurrence
NCT00343356Phase 2Completed
- Sponsor
- Lanzhou University
- Start
- Jun 1996
- Modality
- Vaccines & Immunotherapeutics, DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of epirubicin, bcg vaccine in bladder cancer, sponsored by Lanzhou University. Started Jun 1996; status: completed.
02
Drugs
epirubicinbcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00343356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343356.